HMP To Acquire Imedex

8/29/17

HMP, a leading healthcare education and events company, today announced it has entered into a definitive agreement to acquire Imedex, a privately held global medical education company. Terms of the agreement were not disclosed.

With this combination, HMP strengthens its position as a foremost producer of healthcare events for the global healthcare community. The transaction marks a significant step for HMP in executing its "events first" strategy and expands the company's footprint in global markets and in the highly attractive healthcare verticals of oncology, hematology, and gastroenterology.

"The acquisition of Imedex aligns perfectly with our strategy and represents an extremely important milestone in our vision as we aim to become the world's leading producer of healthcare events and education, with a focus on improving patient care," said Jeff Hennessy, chairman and CEO, HMP. "Imedex provides the perfect platform on which to expand our portfolio. I am enthusiastic about the Imedex leadership—Dan Lowrie and Chris Bolwell—joining our company and look forward to working with them to realize the considerable potential of the combined business."

The Imedex portfolio includes three major medical meetings: World Congress on Gastrointestinal Cancer, the largest gastrointestinal cancer meeting in the world; Advances in IBD (AIBD), focused on professionals who treat and manage patients with inflammatory bowel diseases; and Lymphoma & Myeloma, an international congress on hematological malignancies.

Following completion of the transaction, Imedex will become a fully owned subsidiary of HMP. Leadership will include Dan Lowrie, who will assume the title of president of Imedex, and Chris Bolwell, who will assume the title of executive vice president. The Imedex headquarters will remain in Alpharetta, GA.

"This is an exciting new chapter for Imedex," said Dan Lowrie, CEO, Imedex. "This agreement represents a significant opportunity for Imedex to join a thriving and well-run organization like HMP, one that possesses incredible expertise in healthcare events and a deep commitment to education, and one that values our conferences, the relationships we have built with our learners, is enthusiastic about investing in our people and platforms, and is firmly committed to accelerating our growth."

This is the second major acquisition for HMP this year. In February, the company announced it had acquired EMS World from Southcomm, which includes EMS World Expo, North America's largest EMT and paramedic event, named one of the 50 fastest growing trade shows by Trade Show Executive magazine.

About HMP HMP is a multichannel leader in healthcare events and education, with a mission to improve patient care. The company produces accredited medical education events and clinically relevant, evidence-based content for the healthcare community across a range of therapeutic areas. Its brands include Consultant, the monthly, award-winning journal relied upon by primary care providers; Psych Congress, the largest independent mental health meeting in the U.S.; EMS World Expo, North America's largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP is supported by its lead investor, Susquehanna Growth Equity, LLC (SGE). For more information, visit hmpholdings.com.

About Imedex Imedex® is an industry leader in the creation of independent, accredited medical education for healthcare professionals that improves patient care around the world. With an emphasis in oncology, hematology, and gastroenterology, the company develops high-quality scientific programming that translates the latest research into clinically relevant information. Imedex provides more than 50,000 e-learning experiences annually and since 2001, its live conferences have welcomed more than 100,000 attendees. The company operates in the United States, Europe, and Asia. For more information, visit imedex.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.